MPe25-Granada Vision and Eye Research Team (G-VERT) (Emerging)
Precision Medicine / IBS-MPe25 / Emerging
This research group has the will and vocation to collaborate with other consolidated research groups, to establish a milestone in ophthalmological research in our city with the creation of the first research group in our specialty, and to encourage new generations to join to this world, forming solid work ties between basic and clinical research, and patient care, in order to establish ourselves as a benchmark in translational research.
All the members have developed in the world of research collaborating with other disciplines, within consolidated groups at a national/international level.
The creation of this group could greatly enhance ophthalmological research within Ibs.GRANADA, both by the group itself and by others with whom we already collaborate on an occasional basis.
Research lines
- Analysis of biomarkers of activity and severity by multimodal study in patients with thyroid ophthalmopathy
- Regenerative medicine and advanced therapies in ophthalmology
- Keratoconus and other corneal degenerations
- Innovation in diagnosis and ophthalmological surgical techniques
FRANCISCO ZAMORANO MARTIN
JUAN FRANCISCO RAMOS LOPEZ
IGNACIO MOLINA LEYVA
SANTIAGO ORTIZ PEREZ
Understanding Visual Disorders through Correlation of Clinical and Radiological Findings
RADIOGRAPHICS, 2024;
FI: 5,2; D1
New developments in the management of persistent corneal epithelial defects
SURVEY OF OPHTHALMOLOGY, 2024;
FI: 5,2; D1
Primary Localized Conjunctival Amyloidosis
OPHTHALMOLOGY, 2024;
FI: 13,2; D1
A Comparative Analysis of the Ocular Microbiome: Insights into Healthy Eyes and Anophthalmic Sockets
MICROORGANISMS, 2024;
FI: 4,1; Q2
An Unusual Case of an Intradiploic Arachnoid Cyst of the Orbit
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2024;
FI: 1,2; Q3
Laser-induced maculopathy after iris depigmentation cosmetic treatment
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2023;
FI: 4,2; Q1
Surveying a Sample of the Spanish Ophthalmologic Community about Vaccination against Herpes Zoster
VACCINES, 2023;
FI: 7,8; Q1
Clinical outcomes of presbyopia correction with the latest techniques of presbyLASIK: a systematic review
EYE, 2023;
FI: 3,9; Q1
Ocular Surface Microbiota in Naive Keratoconus: A Multicenter Validation Study
JOURNAL OF CLINICAL MEDICINE, 2023;
FI: 3,9; Q2
Corneal densitometry patterns in Descemet membrane endothelial keratoplasty and Descemet stripping automated keratoplasty
INTERNATIONAL OPHTHALMOLOGY, 2023;
FI: 1,6; Q4
Exploring the Healthy Eye Microbiota Niche in a Multicenter Study
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022;
FI: 6,208; Q1
Fluid misdirection syndrome associated with endothelial keratoplasty: A multicenter case series
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022;
FI: 4,383; Q1
New algorithm for corneal densitometry assessment based on anterior segment optical coherence tomography
EYE, 2022;
FI: 4,456; Q1
Small-aperture intracorneal inlay implantation in emmetropic presbyopic patients: a systematic review
EYE, 2022;
FI: 4,456; Q1
Previous segment involvement in Epstein-Barr virus: a review
ACTA OPHTHALMOLOGICA, 2022;
FI: 3,988; Q2
Study of the ocular surface microbiota in Graves' disease with and without ophthalmopathy.
Funder: FIBAO Foundation
File number: INTRAIBS-PI-2023-03
Execution time: 05/04/2024 - 05/04/2025
IP: SANTIAGO ORTIZ PEREZ
A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy, safety, and tolerability of subcutaneous teprotumumab in participants with moderately to severely active thyroid eye disease.
Funder: HORIZON THERAPEUTICS USA, INC.
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 25/11/2024 - 30/01/2026
IP: SANTIAGO ORTIZ PEREZ
A phase III, randomized, double-blind, placebo-controlled study of the efficacy and safety of STN1013800 (oxymetazoline HCl 0,1% eye drops) used twice daily (BID) for the treatment of acquired blepharoptosis. LIDRISE
Financier: PAREXEL INTERNATIONAL (IRL) LIMITED
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 24/09/2024 - 30/06/2026
IP: SANTIAGO ORTIZ PEREZ
A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Moderate-To-Severe Thyroid Eye Disease
Financier: ROCHE FARMA, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 15/11/2023 - 30/12/2025
IP: SANTIAGO ORTIZ PEREZ
